Alibin medicin AB

Active
559239-6880Limited company (AB)Registered 2020TÄBY

Key figures

280 000 kr−43,0%
Revenue 2025
−32,2%
Average annual change 2023–2025
0200 k400 k600 k800 k202320242025

Key figures

2025

Summary: Alibin medicin AB

What kind of company is it?

Alibin medicin AB (org. no. 559239-6880) is a limited company (AB). The company was registered in 2020 and has existed for 6 years. Registered seat: Täby. Industry according to Statistics Sweden: general primary medical practice activities (SNI 86211).

How is the company doing financially?

Net sales in financial year 2025 were 280 000 kr, down 43,0 % on the previous year (491 000 kr). From 2023 to 2025, net sales declined by an average of 32,2 % per year. Net profit for 2025 was 181 543 kr (64,8 % of net sales). The company was profitable in all 3 reported financial years. At the end of financial year 2025, total assets were 1 323 285 kr and equity 870 589 kr (equity ratio 65,8 %). The annual report for 2025 proposes a dividend of 200 000 kr.

Where does the data come from and how up to date is it?

Company details and digitally filed annual reports come from the open data of the Swedish Companies Registration Office (Bolagsverket) and the industry code from Statistics Sweden (CC BY 2.5 SE); bolagsprofil.se updates them daily. The latest annual report is signed by one person. Data as of 2026-11-16. Changes, averages and ratios are calculated by bolagsprofil.se from open data and are not an official assessment.

Dividend

from the annual report
2025

Proposed dividend 200 000 kr.

History
2025200 000 kr
2024209 000 kr
Summary of annual reports2023–2025
202320242025
Sales revenue609 000491 000280 000
Profit for the reporting year402 216240 553181 543
Retained earnings of previous periods———
Total assets1 375 4231 397 4691 323 285
Total liabilities513 930499 423452 696
Total equity861 493898 046870 589
Employees———
Proposed dividend—209 000200 000

A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.